Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

Haematologica

Volumn 97, Issue 11, 2012, Pages 1736-1742

  Karp, Judith E ^a   Garrett Mayer, Elizabeth ^b   Estey, Elihu H ^c   Rudek, Michelle A ^a   Douglas Smith, B ^a   Greer, Jacqueline M ^a   Michelle Drye, D ^a   Mackey, Karen ^a   Dorcy, Kathleen Shannon ^c   Gore, Steven D ^a   Levis, Mark J ^a   McDevitt, Michael A ^a   Carraway, Hetty E ^a   Pratz, Keith W ^a   Gladstone, Douglas E ^a   Showel, Margaret M ^a   Othus, Megan ^c   Austin Doyle, L ^a   Wright, John J ^d   Pagel, John M ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute myelogenous leukemia; Ara C; Flavopiridol; Mitoxantrone; Poor risk

Indexed keywords

CD135 ANTIGEN; CYTARABINE; FLAVOPIRIDOL; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DEATH; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEART DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERKALEMIA; INCIDENCE; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PIPERIDINES; SURVIVAL RATE;

EID: 84868596277     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.062539     Document Type: Article

References (38)

1. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-35.
2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-15.
3. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-18.
4. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5.
5. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1995;56(11):4856-61.
6. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK 4 in human breast carcinoma cells. Cancer Res. 1996;56 (14):2973-8.
7. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, et al. Downregulation of Cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999;59(18):4634-43.
8. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 2001; 276(34):31793-9.
9. Decker RH, Dai Y, Grant S. The cyclindependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Diff. 2001;8(7):715-24.
10. Gojo I, Zhang B, Fenton RG. The cyclindependent kinase inhibitor Flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8 (8):3527-38.
11. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, et al. Genomicscale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001;2 (10):1-11.
12. Lee YK, Isham CR, Kaufmann SH, Bible KC. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther. 2006;5 (1):138-48.
13. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 2000;92(5):376-87.
14. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770-83.
15. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Cancer Res. 2003;63(8):1822-33.
16. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-Darabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005;11(23):8403-12.
17. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenberg C, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a Phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007;13(15 Pt 1):4467-73.
18. Karp JE, Blackford A, Smith BD, Alino K, Hatfield-Seung A, Bolanos-Meade J, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor risk acute myelogenous leukemia. Leuk Res. 2010;34:877-82.
19. Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, et al. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011;117(12):3302-10
20. Bible KC, Kaufmann SH. Cytotoxic synergy between Flavopiridol (NSC 649890, L86-8278275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997;57(16):3375-80.
21. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a Phase I clinical trial. Clin Cancer Res. 2003;9(1):307-15.
22. Byrd JC, Shinn C, Wasalenko JK, Fuchs EJ, Lehman TA, Nguyen PL, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92(10):3804-16.
23. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever M, Rai K, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11(11):4176-81.
24. Flinn IW, Byrd JC, Bartlett N, Kipps TJ, Gribben D, Thomas RA, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005;29(11): 1253-7.
25. Tan AR, Headlee D, Messman R, Sausville EA, Arbuck SG, Murgo AJ et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol. 2002;20(19):4074-82.
26. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule of flavopiridol is associated with marked clinical activity in refractory, genetically high risk chronic lymphocytic leukemia. Blood. 2007;109(2):399-404.
27. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27(35):6012-8.
28. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113(12):2637-45.
29. Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, et al. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed and refractory acute leukemias. Haematol. 2010;95(7):1098-105.
30. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-15.
31. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69(12):1375-81.
32. Dohner H, Estey EH, Amadori S, Applebaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74.
33. Koyama T, Chen H. Proper inference form Simon's two-stage designs. Stat Med. 2008; 27(16):3145-54.
34. Rudek MA, Bauer JS, Lush RM III, Stinson SF, Senderowicz AM, Headlee DJ, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37(10):1369-74.
35. Rai K, Holland J, Glidewell O, Weinberg V, Brunner K, Obrecht JP, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58(6):1203-12.
36. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. New Engl J Med. 2009;361(13):1235-48.
37. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. New Engl J Med. 2009;361(13): 1249-59.
38. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003;102(2):442-8.